Pa­piernik named chair­man at Sofinno­va Part­ners; Cara shares surge on pos­i­tive da­ta for ure­mic pru­ri­tus

→ Twen­ty years af­ter join­ing Sofinno­va Part­ners in Paris, An­toine Pa­piernik is tak­ing the chair­man’s post. Pa­piernik is well known in VC cir­cles on both sides of the At­lantic, and played a lead­ing role in­vest­ing on a long list of biotechs like Acte­lion and Pro­QR. Pa­piernik suc­ceeds De­nis Luc­quin who re­mains a Man­ag­ing Part­ner.

→ Shares of Cara Ther­a­peu­tics $CARA shot up 15% this morn­ing af­ter the Stam­ford, CT based biotech re­port­ed pos­i­tive top-line re­sults demon­strat­ing from Part A of its Phase II/III tri­al show­ing that I.V. CR845 met both pri­ma­ry and sec­ondary end­points for ef­fi­ca­cy (re­duced itch­ing and im­proved qual­i­ty of life, re­spec­tive­ly) in pa­tients with ure­mic pru­ri­tus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.